Intra-Cellular Poised To Add MDD To Caplyta’s Label
Second Phase III Is Positive
Caplyta succeeded in a second Phase III study as adjunctive therapy for major depression, putting the schizophrenia/bipolar disorder drug on track for sNDA filing later in 2024.
